Compare MDV & ELTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MDV | ELTX |
|---|---|---|
| Founded | 2015 | 2011 |
| Country | United States | United States |
| Employees | 9 | N/A |
| Industry | Transportation Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 187.5M | 185.4M |
| IPO Year | N/A | 2014 |
| Metric | MDV | ELTX |
|---|---|---|
| Price | $18.00 | $4.11 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 3 |
| Target Price | $18.00 | $18.00 |
| AVG Volume (30 Days) | 55.5K | ★ 3.3M |
| Earning Date | 05-08-2026 | 05-12-2026 |
| Dividend Yield | ★ 7.50% | N/A |
| EPS Growth | N/A | ★ 39.29 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $2,301,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $8.56 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $13.80 | $2.66 |
| 52 Week High | $18.83 | $16.00 |
| Indicator | MDV | ELTX |
|---|---|---|
| Relative Strength Index (RSI) | 50.81 | 32.85 |
| Support Level | $17.60 | N/A |
| Resistance Level | $18.75 | $9.95 |
| Average True Range (ATR) | 0.37 | 1.52 |
| MACD | -0.13 | -1.04 |
| Stochastic Oscillator | 30.33 | 10.79 |
Modiv Industrial Inc is a pioneer in the direct-to-consumer commercial real estate product industry. It provides individual investors access to real estate and real estate-related investments designed to provide both income and long-term growth. The company has invested in single-tenant income-producing properties. Its current business consists of owning, managing, operating, leasing, acquiring, investing in, and disposing of commercial real estate assets utilized for industrial manufacturing, as well as a few non-core assets. All of the company's consolidated revenues are derived from the company's consolidated real estate properties.
Elicio Therapeutics Inc is a clinical-stage biotechnology company advancing novel immunotherapies for the treatment of cancer, including mKRAS-positive pancreatic cancer, colorectal cancer (CRC), lung cancer, and other mKRAS-positive cancers. The Company focuses on developing effective, off-the-shelf immunotherapies using its proprietary Amphiphile (AMP) technology, which aims to enhance the education, activation, and amplification of cancer-specific T cells to promote durable cancer immunosurveillance. Its clinical pipeline includes ELI-002 7P, a lymph node-targeted cancer immunotherapy currently being evaluated in a Phase 2 study for mKRAS pancreatic ductal adenocarcinoma (PDAC), a common form of pancreatic cancer.